FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285263320> ?p ?o ?g. }

• W4285263320 endingPage "175883592210994" @default.
• W4285263320 startingPage "175883592210994" @default.
• W4285263320 abstract "The response rate to sorafenib is limited for unresectable hepatocellular carcinoma (HCC). Little is known about the long-term outcomes of objective responders. The role of second-line therapies on the survival of sorafenib-responders is unclear. We aimed to delineate the long-term outcomes and the role of subsequent treatment after responding to sorafenib.From September 2012 to December 2019, 922 patients who received sorafenib treatment for unresectable HCC were retrospectively reviewed. Of these, 21 (2.3%) achieved a complete response (CR) and 54 (5.9%) had a partial response (PR) based on mRECIST criteria. Factors associated with survivals were analyzed.During the median follow-up of 35.3 months, the median duration of response was 18.3 months (range: 2.3-45.5) for patients achieving CR and 10.0 months (range: 1.9-60.3) for PR. The median overall survival (OS) was 39.5 months [95% confidence interval (CI): 28.4-50.5] including values not yet estimable for CR and 25.8 months for PR. Patients who experienced treatment-related adverse events (TRAEs) had better median OS than those without (44.9 versus 18.1 months, p = 0.003). Eventually, 53 patients developed tumor progression; 30 patients received second-line systemic treatment including nivolumab (n = 8), regorafenib (n = 15), and chemotherapy (n = 7). Sorafenib-nivolumab sequential therapy provided the best median OS versus sorafenib-regorafenib and sorafenib-chemotherapy in these patients (55.8, 39.5, and 25.5 months), respectively.The response is durable for advanced HCC patients with CR or PR to sorafenib. Subsequent immunotherapy seems to provide the best survival. This information is important for characterizing outcomes of sorafenib-responders and the choice of sequential treatment." @default.
• W4285263320 created "2022-07-14" @default.
• W4285263320 creator A5001655765 @default.
• W4285263320 creator A5008219887 @default.
• W4285263320 creator A5017637849 @default.
• W4285263320 creator A5026090288 @default.
• W4285263320 creator A5026202909 @default.
• W4285263320 creator A5031663953 @default.
• W4285263320 creator A5036469662 @default.
• W4285263320 creator A5050085113 @default.
• W4285263320 creator A5057044812 @default.
• W4285263320 creator A5074334575 @default.
• W4285263320 creator A5077269939 @default.
• W4285263320 date "2022-01-01" @default.
• W4285263320 modified "2023-10-18" @default.
• W4285263320 title "Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma" @default.
• W4285263320 cites W1801847674 @default.
• W4285263320 cites W1892405924 @default.
• W4285263320 cites W1971837077 @default.
• W4285263320 cites W1994193851 @default.
• W4285263320 cites W1994426116 @default.
• W4285263320 cites W2024450952 @default.
• W4285263320 cites W2029029081 @default.
• W4285263320 cites W2035747243 @default.
• W4285263320 cites W2048620946 @default.
• W4285263320 cites W2051664495 @default.
• W4285263320 cites W2079358014 @default.
• W4285263320 cites W2079586464 @default.
• W4285263320 cites W2090359261 @default.
• W4285263320 cites W2101459399 @default.
• W4285263320 cites W2104072969 @default.
• W4285263320 cites W2159026435 @default.
• W4285263320 cites W2163403599 @default.
• W4285263320 cites W2314952680 @default.
• W4285263320 cites W2336895124 @default.
• W4285263320 cites W2557352975 @default.
• W4285263320 cites W2560499218 @default.
• W4285263320 cites W2606367731 @default.
• W4285263320 cites W2706464180 @default.
• W4285263320 cites W2737883024 @default.
• W4285263320 cites W2754555655 @default.
• W4285263320 cites W2799933121 @default.
• W4285263320 cites W2803637437 @default.
• W4285263320 cites W2918131342 @default.
• W4285263320 cites W2948172856 @default.
• W4285263320 cites W2969638445 @default.
• W4285263320 cites W2991557664 @default.
• W4285263320 cites W2999675465 @default.
• W4285263320 cites W3000074215 @default.
• W4285263320 cites W3011688938 @default.
• W4285263320 cites W3021610682 @default.
• W4285263320 cites W3028127717 @default.
• W4285263320 cites W3029320124 @default.
• W4285263320 cites W3037432591 @default.
• W4285263320 cites W3100244773 @default.
• W4285263320 cites W3102699168 @default.
• W4285263320 cites W3120748890 @default.
• W4285263320 cites W3166117708 @default.
• W4285263320 cites W3170242353 @default.
• W4285263320 cites W4200227582 @default.
• W4285263320 cites W4232620598 @default.
• W4285263320 doi "https://doi.org/10.1177/17588359221099401" @default.
• W4285263320 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35646162" @default.
• W4285263320 hasPublicationYear "2022" @default.
• W4285263320 type Work @default.
• W4285263320 citedByCount "1" @default.
• W4285263320 countsByYear W42852633202022 @default.
• W4285263320 crossrefType "journal-article" @default.
• W4285263320 hasAuthorship W4285263320A5001655765 @default.
• W4285263320 hasAuthorship W4285263320A5008219887 @default.
• W4285263320 hasAuthorship W4285263320A5017637849 @default.
• W4285263320 hasAuthorship W4285263320A5026090288 @default.
• W4285263320 hasAuthorship W4285263320A5026202909 @default.
• W4285263320 hasAuthorship W4285263320A5031663953 @default.
• W4285263320 hasAuthorship W4285263320A5036469662 @default.
• W4285263320 hasAuthorship W4285263320A5050085113 @default.
• W4285263320 hasAuthorship W4285263320A5057044812 @default.
• W4285263320 hasAuthorship W4285263320A5074334575 @default.
• W4285263320 hasAuthorship W4285263320A5077269939 @default.
• W4285263320 hasBestOaLocation W42852633201 @default.
• W4285263320 hasConcept C121608353 @default.
• W4285263320 hasConcept C126322002 @default.
• W4285263320 hasConcept C141071460 @default.
• W4285263320 hasConcept C143998085 @default.
• W4285263320 hasConcept C197934379 @default.
• W4285263320 hasConcept C2776248978 @default.
• W4285263320 hasConcept C2776694085 @default.
• W4285263320 hasConcept C2777701055 @default.
• W4285263320 hasConcept C2778019345 @default.
• W4285263320 hasConcept C2778695046 @default.
• W4285263320 hasConcept C2778822529 @default.
• W4285263320 hasConcept C2779984678 @default.
• W4285263320 hasConcept C2780030458 @default.
• W4285263320 hasConcept C3019096185 @default.
• W4285263320 hasConcept C44249647 @default.
• W4285263320 hasConcept C526805850 @default.
• W4285263320 hasConcept C71924100 @default.
• W4285263320 hasConcept C90924648 @default.

• next